Lipodystrophy in patients naive to HIV protease inhibitors.
about
Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesBody composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors.HIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation.Coronary artery disease and human immunodeficiency virus infection.Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African womenAdverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.Strategies for treating HIV-related lipodystrophy.Nutrition and HIV infection.Evaluation and management of dyslipidemia in patients with HIV infection.Alterations in the gut microbiota associated with HIV-1 infection.HIV and HAART-Associated DyslipidemiaAntiretroviral therapies associated with lipoatrophy in HIV-infected womenFat distribution in women with HIV infection.Fat distribution in men with HIV infection.The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristicsHIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy.A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individualsAdverse effects of antiretroviral therapy for HIV infection: a review of selected topics.Minocycline- and tetracycline-induced hypertriglyceridemia in an HIV-seropositive patient receiving combination antiretroviral therapy.Accelerated Aging in HIV Patients.The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.Treatment of dyslipidemia in HIV-infected patients.Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection.In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.Treatment of dyslipidemia in HIV.Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study.Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors.Body changes: antiretroviral therapy and lipodystrophy syndrome in people living with HIV/AIDS.Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.CT appearances of HIV-related lipodystrophy syndrome.Lipodystrophy syndrome in children infected with human immunodeficiency virus.Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients.[Metabolic alterations in HIV-associated lipodystrophy syndrome].Biochemical Manifestation of HIV Lipodystrophy Syndrome.[Corporal fat distribution and lipidic and glicemic profiles of HIV-infected patients].Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
P2860
Q28775900-83BC617E-0806-4E32-AEF0-BBF5715D9D5AQ31055878-01AD1BD4-C18B-47EA-82A7-8B6A50E2F5FEQ33562238-BD954210-F95B-4974-97E6-8F39FD4E001DQ34052597-4F9C7DE6-17A1-4B38-8270-6BD4D7480E37Q34092346-D0079017-282B-411B-B8B0-0B1953563865Q34138834-AB02AEA7-7073-446A-B89E-2675441C9F8CQ34187120-5377A3F0-3801-4F98-B549-50F54515A627Q34481623-D960E261-823E-4DA0-A78A-119670D342B4Q34564488-4CBDC63C-E450-4750-81B7-66DC0EF2601CQ34743413-CA13C3CC-497B-4F53-80EB-5D0053E793B6Q34986967-8A392071-3786-4B0A-8640-469E5B7B6139Q35020217-00E3911D-485F-4C4A-88D3-8CA7914188C7Q35097650-D695BFD4-3E17-4BB9-80CE-F3597860B3B6Q35194384-676A9BE3-4D4A-4758-A856-BD6704CBD1D0Q35194387-B37C9B9A-330B-4E8B-92D7-48CD8A98E4A4Q35206623-70433EEA-A4C2-4571-87BF-D797755F629FQ35216193-EAAE54ED-F192-417E-8C7A-6875A9EF1E16Q35530469-0D7949A9-938A-45F4-894B-E84487B73107Q36081993-4DFAA1AD-0499-4C5A-9603-B23C5F012AC8Q36714593-BAF84039-0872-497E-8D14-71DCB45369F5Q36919221-1835342B-D774-4600-B533-2FB1BFD4CB4CQ37349834-5CCCC375-A162-4E6C-909E-E82CA62A653EQ37756963-CF5460AF-4B58-4B9D-83D5-B0987F2805F1Q38172305-E726B819-4D9B-4131-B7DE-4B31E28A2591Q38346020-E9E7769C-17DE-4324-971F-5AFF0EE01724Q38363531-1CE5C0EC-7A07-4C66-B895-94D9E895E82FQ39342992-865D37F9-0438-4696-BD4A-7155CABBBE02Q40851323-2BF8E987-2AC7-494A-A4EA-0567D70BFC0FQ43586525-F7CFB5A6-1B78-49E6-BBD4-86E12FD1BE04Q43602324-A44F1104-1BA8-4B1F-BEAE-AFC24782B1C2Q43626545-2DE97383-CB1B-460D-B6D2-57704F02F1AEQ43667547-559738C9-6197-410E-95F4-B37E7D0719BBQ44738362-06526A93-A599-4BD4-9EDD-EEE978D1F03EQ45099760-38033F37-8F7B-41B5-8908-594FB20BE04AQ45800319-2644007B-2E55-45A3-B7C7-93994E25300CQ51473140-155E6EF6-46BF-437F-83DD-E8A3FEC2C301Q51491591-F13B5162-21E0-482A-A3DF-C1A389EE4AD6Q51494133-7B66F549-98E3-40EA-9E53-5DAACC863C9FQ53851252-E2B79123-2D2E-46D7-AC3A-42A129D78155
P2860
Lipodystrophy in patients naive to HIV protease inhibitors.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Lipodystrophy in patients naive to HIV protease inhibitors.
@en
Lipodystrophy in patients naive to HIV protease inhibitors.
@nl
type
label
Lipodystrophy in patients naive to HIV protease inhibitors.
@en
Lipodystrophy in patients naive to HIV protease inhibitors.
@nl
prefLabel
Lipodystrophy in patients naive to HIV protease inhibitors.
@en
Lipodystrophy in patients naive to HIV protease inhibitors.
@nl
P2093
P1433
P1476
Lipodystrophy in patients naive to HIV protease inhibitors.
@en
P2093
Johnson MA
Kinloch-de-Loes S
P304
P356
10.1097/00002030-199904160-00020
P407
P577
1999-04-01T00:00:00Z